STANDARD BIOTOOLS INC.LABEarnings & Financial Report
Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.
Revenue
$21.8M
Gross Profit
$10.6M
Operating Profit
$-25.7M
Net Profit
$-33.5M
Gross Margin
48.8%
Operating Margin
-118.1%
Net Margin
-153.7%
YoY Growth
-3.2%
EPS
$-0.09
STANDARD BIOTOOLS INC. Q2 FY2025 Financial Summary
STANDARD BIOTOOLS INC. reported revenue of $21.8M (down 3.2% YoY) for Q2 FY2025, with a net profit of $-33.5M (up 26.8% YoY) (-153.7% margin). Cost of goods sold was $11.1M, operating expenses totaled $36.3M.
Key Financial Metrics
| Total Revenue | $21.8M |
|---|---|
| Net Profit | $-33.5M |
| Gross Margin | 48.8% |
| Operating Margin | -118.1% |
| Report Period | Q2 FY2025 |
Revenue Breakdown
STANDARD BIOTOOLS INC. Q2 FY2025 revenue of $21.8M breaks down across 3 segments, led by Consumables at $10.5M (48.1% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Consumables | $10.5M | 48.1% |
| Services And Other Revenue | $6.1M | 28.0% |
| Instruments | $5.2M | 24.0% |
STANDARD BIOTOOLS INC. Revenue by Segment — Quarterly Trend
STANDARD BIOTOOLS INC. revenue by segment across the last 4 reported quarters, showing how each business line (such as Consumables and Services And Other Revenue) has evolved quarter over quarter.
| Segment | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q3 FY2024 |
|---|---|---|---|---|
| Consumables | $8.7M | $10.5M | $14.5M | $14.0M |
| Services And Other Revenue | $5.8M | $6.1M | — | — |
| Instruments | $5.1M | $5.2M | $7.8M | — |
STANDARD BIOTOOLS INC. Annual Revenue by Year
STANDARD BIOTOOLS INC. annual revenue history includes year-by-year totals (for example, 2023 revenue was $106.3M).
| Year | Annual Revenue |
|---|---|
| 2023 | $106.3M |
| 2022 | $97.9M |
STANDARD BIOTOOLS INC. Quarterly Revenue & Net Profit History
STANDARD BIOTOOLS INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $19.6M | -11.5% | $-34.7M | -177.4% |
| Q2 FY2025 | $21.8M | -3.2% | $-33.5M | -153.7% |
| Q1 FY2025 | $40.8M | -10.4% | $-26.0M | -63.8% |
| Q3 FY2024 | $22.1M | -12.9% | $-26.9M | -122.0% |
| Q2 FY2024 | $22.5M | -18.7% | $-45.7M | -203.3% |
| Q1 FY2024 | $45.5M | +81.3% | $-32.2M | -70.6% |
| Q4 FY2023 | $28.2M | +4.3% | $-19.8M | -70.2% |
| Q3 FY2023 | $25.4M | -1.1% | $-21.0M | -82.8% |
Income Statement
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $25.4M | $28.2M | $45.5M | $22.5M | $22.1M | $40.8M | $21.8M | $19.6M |
| YoY Growth | -1.1% | 4.3% | 81.3% | -18.7% | -12.9% | -10.4% | -3.2% | -11.5% |
Balance Sheet
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $339.3M | $323.1M | $777.7M | $708.7M | $681.5M | $579.6M | $557.0M | $539.6M |
| Liabilities | $159.8M | $159.9M | $200.4M | $198.5M | $192.2M | $125.0M | $132.4M | $140.0M |
| Equity | $-131.7M | $-148.1M | $577.3M | $510.3M | $489.3M | $454.6M | $424.5M | $399.7M |
Cash Flow
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-11.4M | $-14.1M | $-62.5M | $-39.0M | $-27.9M | $-30.3M | $-20.7M | $-22.2M |